BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

Study acronym: BIOVAS
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study title expanded, about 2 wordsv12
  2. Primary endpoint revised
    • Secondary endpoints: 9 to 10
    • Study arms: 2 to 3
    v11
  3. Primary completion date: Feb 25, 2024 to Oct 30, 2026
    • Start date: Aug 31, 2019 to Oct 30, 2019
    • Study completion date: May 25, 2024 to Sep 1, 2027
    • Study arms: 1 to 2
    v10
  4. Primary completion date: Feb 25, 2023 to Feb 25, 2024
    • Study completion date: Aug 25, 2023 to May 25, 2024
    v9
  5. Site contact updatedv8
Show 6 earlier versionsHide 6 earlier versions
  1. Study description expanded, about 279 wordsv7
  2. Primary completion date: Dec 25, 2021 to Feb 25, 2023
    • Study completion date: May 25, 2022 to Aug 25, 2023
    v6
  3. Eligibility criteria shortened, about 8 wordsv5
  4. Primary completion date: Jun 25, 2020 to Dec 25, 2021
    • Study completion date: Oct 25, 2020 to May 25, 2022
    v4
  5. Eligibility criteria revisedv3
  6. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study completion date: Sep 25, 2020 to Oct 25, 2020
    • Study description expanded, about 65 words
    • Site details revised
    • Eligibility criteria shortened, about 4 words
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ruijin Hospital
385 trials monitored
See 13 trials at risk
Sarcoma
1,031 trials monitored
See 72 trials at risk
The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A\>G polymorphism as predictive biomarker
Trial Details
NCT Number NCT04072042
Lead Sponsor Ruijin Hospital
Conditions
(from sponsor)		 Sarcoma
Related terms Sarcoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov